Zevra Therapeutics (ZVRA) Cash from Operations Growth (1y) (2015 - 2026)
Zevra Therapeutics (ZVRA) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Zevra Therapeutics |
787.90 Mn |
587.28 Mn |
34.30 Mn |
174.70% |
| Date | Value |
|---|
| Mar 31, 2026 |
174.70% |
| Dec 31, 2025 |
133.94% |
| Sep 30, 2025 |
125.96% |
| Jun 30, 2025 |
81.16% |
| Mar 31, 2025 |
49.14% |
| Dec 31, 2024 |
-0.57% |
| Sep 30, 2024 |
-291.98% |
| Jun 30, 2024 |
-119.54% |
| Mar 31, 2024 |
-299.63% |
| Dec 31, 2023 |
-262.12% |
| Sep 30, 2023 |
29.86% |
| Jun 30, 2023 |
-112.09% |
| Mar 31, 2023 |
-13.85% |
| Dec 31, 2022 |
-426.18% |
| Sep 30, 2022 |
-141.68% |
| Jun 30, 2022 |
-124.72% |
| Mar 31, 2022 |
-37.39% |
| Dec 31, 2021 |
19.92% |
| Sep 30, 2021 |
-159.75% |
| Jun 30, 2021 |
657.09% |
